Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Sep 14:14:1216817.
doi: 10.3389/fendo.2023.1216817. eCollection 2023.

Research progress on the role of the Wnt signaling pathway in pituitary adenoma

Wencai Wang  1 , Luyao Ma  1 , Yongqiang Zhao  1 , Menghao Liu  1 , Wei Ye  1 , Xianfeng Li  1
Affiliations
Review

Research progress on the role of the Wnt signaling pathway in pituitary adenoma

Wencai Wang et al. Front Endocrinol (Lausanne). .

Abstract

Pituitary adenoma (PA) is the third most common central nervous system tumor originating from the anterior pituitary, but its pathogenesis remains unclear. The Wnt signaling pathway is a conserved pathway involved in cell proliferation, Self-renewal of stem cells, and cell differentiation. It is related to the occurrence of various tumors, including PA. This article reviews the latest developments in Wnt pathway inhibitors and pathway-targeted drugs. It discusses the possibility of combining Wnt pathway inhibitors with immunotherapy to provide a theoretical basis for the combined treatment of PA.

Keywords: PA; TME; Wnt pathway inhibitors; Wnt signaling pathway; non-coding RNA; targeted drugs.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Wnt signaling pathway.
Figure 2
Figure 2
Drugs targeting wnt signaling pathway.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Ostrom QT, Gittleman H, Truitt G, Boscia A, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011-2015. Neuro Oncol (2018) 20(suppl_4):iv1–iv86. doi: 10.1093/neuonc/noy131 - DOI - PMC - PubMed
    1. Kessel KA, Diehl CD, Oechsner M, Meyer B, Gempt J, Zimmer C, et al. Patient-Reported Outcome (PRO) as an Addition to Long-Term Results after High-Precision Stereotactic Radiotherapy in Patients with Secreting and Non-Secreting Pituitary Adenomas: A Retrospective Cohort Study up to 17-Years Follow-Up. Cancers (Basel) (2019) 11(12). doi: 10.3390/cancers11121884 - DOI - PMC - PubMed
    1. Aflorei ED, Korbonits M. Epidemiology and etiopathogenesis of pituitary adenomas. J Neurooncol (2014) 117(3):379–94. doi: 10.1007/s11060-013-1354-5 - DOI - PubMed
    1. Gondim JA, de Almeida JP, de Albuquerque LA, Schops M, Gomes E, Ferraz T. Headache associated with pituitary tumors. J Headache Pain (2009) 10(1):15–20. doi: 10.1007/s10194-008-0084-0 - DOI - PMC - PubMed
    1. Al-Dahmani K, Mohammad S, Imran F, Theriault C, Doucette S, Zwicker D, et al. Sellar masses: an epidemiological study. Can J Neurol Sci (2016) 43(2):291–7. doi: 10.1017/cjn.2015.301 - DOI - PubMed